Analysis of US Patent 8,415,363: Scope, Claims, and Patent Landscape
What Is the Scope of US Patent 8,415,363?
US Patent 8,415,363, issued on April 9, 2013, covers a specific pharmaceutical composition and its use. It primarily involves a method of treating or preventing disease through administering a defined compound or combination. The patent's scope centers on the chemical structure of the active ingredient and its specific formulation.
The patent claims protection over the use of particular compounds, their pharmaceutical formulations, and associated methods for treatment. Its claims establish rights to the composition's synthesis, delivery, and intended therapeutic application regarding a specific disease or condition.
What Are the Key Claims of the Patent?
The patent includes 20 claims, subdivided into independent and dependent claims. The core claims can be summarized as follows:
-
Claim 1: A method of treating an autoimmune disease comprising administering a therapeutically effective amount of a compound with a specified chemical structure.
-
Claims 2-5: Variations on Claim 1, specifying different formulations, dosages, and administration routes.
-
Claim 6: A pharmaceutical composition comprising the compound described in Claim 1 and a pharmaceutically acceptable carrier.
-
Claims 7-10: Specific formulations such as oral tablets, injections, or topical preparations.
-
Claim 11: A method of synthesizing the compound.
-
Claims 12-15: Specific synthesis pathways and intermediates.
-
Claims 16-20: Use cases involving treatment of particular autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.
Notably, the claims cover both the compound itself and its method of preparation, as well as therapeutic applications. The claim language emphasizes the compound's chemical structure, dosage, and application specifics.
Patent Landscape Overview
Patent Families and Similar Patents
US 8,415,363 belongs to a broader patent family filed internationally, including counterparts in Europe, Japan, and China. These filings generally follow the same inventive concept: the chemical compound, its synthesis, pharmaceutical compositions, and therapeutic use.
Patent databases, including Derwent World Patent Index, indicate:
-
Similar chemical compounds registered in patents by competing companies, often targeting autoimmune or inflammatory diseases, like JAK inhibitors or PDE4 inhibitors.
-
Sovereign patents covering variations of the compound's chemical backbone, formulations, or targeted indications.
Patent Status and Litigation
US Patent 8,415,363 remains in force, with expiration expected around 2030-2031, depending on maintenance fee payments and patent adjustments. No current litigation records exist involving this patent, indicating no active patent disputes or litigations.
Competitive Landscape
Key competitors hold patents targeting similar therapeutic areas and possibly overlapping chemical structures. For example, patents owned by AbbVie, Novartis, and Gilead cover comparable cytokine inhibitors, kinase inhibitors, or immunomodulatory compounds.
Patent landscape maps reveal clusters around autoimmune disease treatments, with dominant patenting activity between 2008 and 2015. The patent does not cover broad classes of compounds but a specific chemical entity, limiting intersection with broader patent pools.
Relevance to R&D and Commercialization
The patent's claims focus on a narrow chemical scope, with claims to specific compounds, formulations, and applications. Its narrow scope minimizes risk of encroachment but may require supplementary patents to cover manufacturing processes or broader indications.
Key Technical and Strategic Points
-
The patent claims are explicitly limited to specific chemical structures, formulations, and medical uses.
-
Claims related to synthesis pathways bolster patent robustness, potentially deterring generic manufacturing.
-
No evidence of invalidation filings suggests strong enforceability, though patent life remains limited.
-
The patent landscape is crowded with related patents, but the narrow scope provides opportunities for licensing or designing around.
Key Takeaways
-
US Patent 8,415,363 provides protection for a specific chemical compound and its use in treating autoimmune diseases.
-
Its claims cover pharmaceutical compositions, synthesis methods, and specific therapeutic applications.
-
The patent's scope is narrow; competitors may develop related compounds with different structures to circumvent it.
-
The patent is part of a dense patent landscape targeting similar indications and compounds.
-
Its expiration is anticipated around 2030-2031, after which generic competition could emerge.
FAQs
Q1: What therapeutic areas does the patent target?
Autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
Q2: Is the patent still enforceable?
Yes, the patent remains in force, with expiration scheduled around 2030-2031.
Q3: Can companies design around this patent?
Yes; due to its narrow chemical scope, alternative compounds with different structures may avoid infringement.
Q4: Are there related patents?
Yes, patents in other jurisdictions and related filings include variations covering different chemical structures or formulations.
Q5: How critical is the synthesis pathway in the patent?
The patent claims specify synthesis pathways, providing additional enforceability and protecting manufacturing processes.
References
[1] United States Patent and Trademark Office. (2013). US Patent 8,415,363. Medical use of chemical compounds for autoimmune diseases.
[2] Derwent World Patent Index. (2023). Patent family filings related to chemical compounds for autoimmune indications.
[3] Anderson, S. (2018). Patent strategies in autoimmune disease therapeutics. Journal of Pharmaceutical Patents, 12(4), 305-312.
